Preview
Flow Neuroscience has launched FL-100 in the United States, marking the first FDA-approved at-home transcranial direct current stimulation (tDCS) treatment for moderate to severe major depressive disorder (MDD). The prescription-only device, which combines…
The complete summary, “why it matters” analysis and the original source link are available to members.
tdcsdepressionfda-approvedat-home-treatmentneurostimulation